EP1009407A2 - Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie - Google Patents

Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie

Info

Publication number: EP1009407A2
Authority: EP; European Patent Office
Prior art keywords: noribogaine; patient; administered; opioid; drug
Prior art date: 1997-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP98944698A

Other languages

German (de)

English (en)

Other versions

EP1009407B1 (fr

Inventor

Deborah C. Mash

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novoneuron Inc

Original Assignee

Novoneuron Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-04

Filing date

1998-09-03

Publication date

2000-06-21

1998-09-03 Application filed by Novoneuron Inc filed Critical Novoneuron Inc

1998-09-03 Priority to EP03075683A priority Critical patent/EP1327447B1/fr

1998-09-03 Priority to EP10180121.5A priority patent/EP2338494B1/fr

1998-09-03 Priority to EP10170898A priority patent/EP2246058A1/fr

2000-06-21 Publication of EP1009407A2 publication Critical patent/EP1009407A2/fr

2004-04-28 Application granted granted Critical

2004-04-28 Publication of EP1009407B1 publication Critical patent/EP1009407B1/fr

2018-09-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

RAUCDOKTMDOIPF-UHFFFAOYSA-N hydroxyibogamine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-UHFFFAOYSA-N 0.000 title claims abstract description 94
RAUCDOKTMDOIPF-RYRUWHOVSA-N noribogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-RYRUWHOVSA-N 0.000 title claims abstract description 94
208000002193 Pain Diseases 0.000 title claims abstract description 20
230000036407 pain Effects 0.000 title claims abstract description 20
208000011117 substance-related disease Diseases 0.000 title claims description 15
206010013663 drug dependence Diseases 0.000 title claims description 13
238000011282 treatment Methods 0.000 title abstract description 21
238000000034 method Methods 0.000 claims abstract description 40
229940079593 drug Drugs 0.000 claims abstract description 29
239000003814 drug Substances 0.000 claims abstract description 29
239000003401 opiate antagonist Substances 0.000 claims abstract description 19
229960004127 naloxone Drugs 0.000 claims abstract description 18
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims abstract description 18
208000024891 symptom Diseases 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 15
239000003887 narcotic antagonist Substances 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 9
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 9
229960003086 naltrexone Drugs 0.000 claims description 9
206010013654 Drug abuse Diseases 0.000 claims description 8
230000037396 body weight Effects 0.000 claims description 8
238000002560 therapeutic procedure Methods 0.000 claims description 7
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
206010012335 Dependence Diseases 0.000 claims description 5
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 4
230000036592 analgesia Effects 0.000 claims description 4
229960001797 methadone Drugs 0.000 claims description 4
239000000014 opioid analgesic Substances 0.000 claims description 4
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 3
239000000730 antalgic agent Substances 0.000 claims description 3
229960003920 cocaine Drugs 0.000 claims description 3
229960002069 diamorphine Drugs 0.000 claims description 3
229940005483 opioid analgesics Drugs 0.000 claims description 2
230000003533 narcotic effect Effects 0.000 claims 1
230000037317 transdermal delivery Effects 0.000 claims 1
HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 19
VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 17
OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 17
AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 17
239000002552 dosage form Substances 0.000 description 10
XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 9
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 6
108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
239000000126 substance Substances 0.000 description 5
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
229960005181 morphine Drugs 0.000 description 4
229960000938 nalorphine Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
229940076279 serotonin Drugs 0.000 description 4
239000007787 solid Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000000380 hallucinogen Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000004081 narcotic agent Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
230000000542 thalamic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
108091006027 G proteins Proteins 0.000 description 2
102000030782 GTP binding Human genes 0.000 description 2
108091000058 GTP-Binding Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000000112 Myalgia Diseases 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241001246918 Tabernanthe iboga Species 0.000 description 2
230000009471 action Effects 0.000 description 2
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
229960001736 buprenorphine Drugs 0.000 description 2
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010520 demethylation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
229930005303 indole alkaloid Natural products 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
102000051367 mu Opioid Receptors Human genes 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000010695 polyglycol Substances 0.000 description 2
229920000151 polyglycol Polymers 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
108020001612 μ-opioid receptors Proteins 0.000 description 2
239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229940127450 Opioid Agonists Drugs 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229940091181 aconitic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000003965 antinociceptive agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
244000309466 calf Species 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
-1 e.g. Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000003400 hallucinatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
MYWUZJCMWCOHBA-UHFFFAOYSA-N n-methyl-1-phenylpropan-2-amine Chemical compound CNC(C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000001962 neuropharmacologic effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000003402 opiate agonist Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940117803 phenethylamine Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000012354 positive regulation of binding Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
239000003762 serotonin receptor affecting agent Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse

Definitions

the invention is also directed to a method for treating drug addiction (involving drug dependency or drug abuse) during withdrawal therapy by administering noribogaine to a patient at a dosage sufficient to reduce or eliminate one or more symptoms associated with withdrawal.
Such symptoms include nausea, vomiting, anxiety, abdominal cramps, muscle pain, chills and headache.
noribogaine treatment decreases the drug cravings normally experienced by addicts after cessation of the self administration of the abused substance.
Noribogaine is especially useful in the treatment of addiction to narcotics such as heroin and methadone. However, it is also useful in treating patients addicted to cocaine, alcohol, amphetamines and combinations of these drugs.

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Addiction (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

EP98944698A 1997-09-04 1998-09-03 Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie Expired - Lifetime EP1009407B1 (fr)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
EP03075683A EP1327447B1 (fr)	1997-09-04	1998-09-03	Noribogaine utilisée pour le traitement de la douleur et de la toxomanie
EP10180121.5A EP2338494B1 (fr)	1997-09-04	1998-09-03	Noribogain utilisée pour le traitement de la douleur et de la toxicomanie
EP10170898A EP2246058A1 (fr)	1997-09-04	1998-09-03	Noribogain utilisée pour le traitement de la douleur et de la toxicomanie

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5792197P	1997-09-04	1997-09-04
US57921P		1997-09-04
PCT/US1998/018284 WO1999011250A2 (fr)	1997-09-04	1998-09-03	Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP03075683A Division-Into EP1327447B1 (fr)	1997-09-04	1998-09-03	Noribogaine utilisée pour le traitement de la douleur et de la toxomanie
EP03075683A Division EP1327447B1 (fr)	1997-09-04	1998-09-03	Noribogaine utilisée pour le traitement de la douleur et de la toxomanie

Publications (2)

Publication Number	Publication Date
EP1009407A2 true EP1009407A2 (fr)	2000-06-21
EP1009407B1 EP1009407B1 (fr)	2004-04-28

Family

ID=22013572

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
EP03075683A Expired - Lifetime EP1327447B1 (fr)	1997-09-04	1998-09-03	Noribogaine utilisée pour le traitement de la douleur et de la toxomanie
EP10180121.5A Expired - Lifetime EP2338494B1 (fr)	1997-09-04	1998-09-03	Noribogain utilisée pour le traitement de la douleur et de la toxicomanie
EP10170898A Withdrawn EP2246058A1 (fr)	1997-09-04	1998-09-03	Noribogain utilisée pour le traitement de la douleur et de la toxicomanie
EP98944698A Expired - Lifetime EP1009407B1 (fr)	1997-09-04	1998-09-03	Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
EP03075683A Expired - Lifetime EP1327447B1 (fr)	1997-09-04	1998-09-03	Noribogaine utilisée pour le traitement de la douleur et de la toxomanie
EP10180121.5A Expired - Lifetime EP2338494B1 (fr)	1997-09-04	1998-09-03	Noribogain utilisée pour le traitement de la douleur et de la toxicomanie
EP10170898A Withdrawn EP2246058A1 (fr)	1997-09-04	1998-09-03	Noribogain utilisée pour le traitement de la douleur et de la toxicomanie

Country Status (9)

Country	Link
US (6)	US7754710B2 (fr)
EP (4)	EP1327447B1 (fr)
AT (2)	ATE265213T1 (fr)
AU (1)	AU754088B2 (fr)
CA (1)	CA2302754C (fr)
DE (1)	DE69823520T2 (fr)
ES (3)	ES2224430T3 (fr)
IL (2)	IL134796A0 (fr)
WO (1)	WO1999011250A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001052851A1 (fr) *	2000-01-22	2001-07-26	Albert Shulman	Methodes de traitement d'abus de substances
DE60238756D1 (de)	2001-05-11	2011-02-10	Endo Pharmaceuticals Inc	Opioid enthaltende arzneiform gegen missbrauch
CA2778114A1 (fr) *	2001-05-11	2002-11-21	Endo Pharmaceuticals, Inc.	Forme posologique d'opioides empechant la consommation abusive
PT2425824T (pt)	2002-04-05	2017-08-23	Mundipharma Farmacêutica Lda	Preparação farmacêutica contendo oxicodona e naloxona
EP1702558A1 (fr)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Procédé et dispositif pour évaluer la fonction de l'activité intestinale
ME03298B (fr)	2009-03-10	2019-07-20	Euro Celtique Sa	Compositions pharmaceutiques à libération immédiate comportant de l'oxycodone et du naloxone
US9394294B2 (en)	2010-05-11	2016-07-19	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) *	2010-05-11	2013-01-29	Demerx, Inc.	Substituted noribogaine
US8765737B1 (en)	2010-05-11	2014-07-01	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
US8637648B1 (en)	2010-06-22	2014-01-28	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en)	2010-06-22	2017-03-07	Demerx, Inc.	N-substituted noribogaine prodrugs
US8741891B1 (en)	2010-06-22	2014-06-03	Demerx, Inc.	N-substituted noribogaine prodrugs
US8802832B2 (en)	2010-06-22	2014-08-12	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
EP2595632A1 (fr) *	2010-07-23	2013-05-29	DemeRx, Inc.	Compositions de noribogaïne
EP2481740B1 (fr)	2011-01-26	2015-11-04	DemeRx, Inc.	Procédés et compositions pour préparer de la noribogaïne à partir de voacangine
US8742096B2 (en) *	2011-03-28	2014-06-03	Demerx, Inc.	Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en)	2011-08-26	2017-04-11	Demerx, Inc.	Synthetic noribogaine
US9040520B2 (en)	2011-09-15	2015-05-26	Demerx, Inc.	Noribogaine salt ansolvates
JP2015509076A (ja) *	2011-12-08	2015-03-26	デメレックス，インコーポレイテッド	ノルイボガインの立体選択的全合成
JP2015509075A (ja) *	2011-12-09	2015-03-26	デメレックス，インコーポレイテッド	ノルイボガインの硫酸エステル
EP2788003A4 (fr) *	2011-12-09	2015-05-27	Demerx Inc	Esters phosphoriques de noribogaïne
CA2858820C (fr)	2012-01-25	2021-08-17	Demerx, Inc.	Voacangine synthetique
US9150584B2 (en)	2012-01-25	2015-10-06	Demerx, Inc.	Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US9045481B2 (en)	2012-12-20	2015-06-02	Demerx, Inc.	Substituted noribogaine
WO2014098877A1 (fr)	2012-12-20	2014-06-26	Demerx, Inc.	Noribogaïne substituée
US8940728B2 (en)	2012-12-20	2015-01-27	Demerx, Inc.	Substituted noribogaine
CA2942638A1 (fr)	2013-03-15	2014-09-18	Demerx, Inc.	Procede pour le traitement avec la noribogaine de l'addiction de patients sous methadone
CN105517551A (zh)	2013-07-23	2016-04-20	欧洲凯尔特公司	用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
US9192570B2 (en)	2013-12-20	2015-11-24	AntiOP, Inc.	Intranasal naloxone compositions and methods of making and using same
KR20160124829A (ko) *	2014-02-18	2016-10-28	데메알엑스, 인크.	노르이보가인 및 관련된 화합물을 이용하는 치료 방법
US9345711B2 (en) *	2014-02-18	2016-05-24	Demerx, Inc.	Methods for acute and long-term treatment of drug addiction
US9561232B2 (en)	2014-02-18	2017-02-07	Demerx, Inc.	Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
KR20160120781A (ko) *	2014-02-18	2016-10-18	데메알엑스, 인크.	약물 중독의 급성 및 장기간 치료 방법
US20150246055A1 (en) *	2014-03-03	2015-09-03	Demerx, Inc.	Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US20150258111A1 (en) *	2014-03-13	2015-09-17	Demerx, Inc.	Methods and compositions for reducing tolerance to opioid analgesics using ibogaine and derivatives thereof
US9591978B2 (en)	2014-03-13	2017-03-14	Demerx, Inc.	Methods and compositions for pre-screening patients for treatment with noribogaine
WO2015142346A1 (fr) *	2014-03-20	2015-09-24	Demerx, Inc.	Procédés et compositions de préparation et de purification de noribogaïne
WO2015195673A2 (fr)	2014-06-18	2015-12-23	Demerx, Inc.	Dérivés d'indole et de benzofurane halogénés d'isoquinuclidène et procédés pour leur préparation.
US9549935B2 (en)	2014-07-14	2017-01-24	Demerx, Inc.	Methods and compositions for treating migraines using noribogaine
US9592239B2 (en)	2014-09-12	2017-03-14	Demerx, Inc.	Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
AU2015353414B2 (en)	2014-11-26	2021-04-29	Demerx, Inc.	Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
EP3340984A4 (fr) *	2015-05-11	2019-06-19	DemeRx, Inc.	Procédés de traitement de la dépendance aux opioïdes et des symptômes de sevrage en utilisant de la noribogaïne
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh)	2019-04-17	2022-01-28	指南针探路者有限公司	用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB841697A (en) *	1956-03-22	1960-07-20	Ciba Ltd	Analgesic compositions
GB924042A (en)	1959-03-05	1963-04-18	Geigy Ag J R	Process for the decarboxylation of alkyl esters of unsaturated, nitrogen-containing carboxylic acids
US3639408A (en)	1967-06-03	1972-02-01	Shionogi & Co	Process for the preparation of isoquinuclidine derivatives
US3516989A (en)	1967-10-02	1970-06-23	American Home Prod	Intermediates for total synthesis of iboga alkaloids and means of preparation
FR7131M (fr)	1968-01-31	1969-07-21
US3557126A (en)	1969-08-14	1971-01-19	American Home Prod	Derivatives of iboga alkaloids
US3574220A (en)	1969-08-14	1971-04-06	American Home Prod	1,7-methano-1h-1-benzazepin-5(4h)-ones
CA982478A (en)	1971-04-12	1976-01-27	Jerome Berk	Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4375414A (en)	1971-05-20	1983-03-01	Meir Strahilevitz	Immunological methods for removing species from the blood circulatory system and devices therefor
US3715361A (en) *	1971-10-08	1973-02-06	American Cyanamid Co	Acyl derivatives of 10-methoxyibogamine
US3875011A (en)	1972-11-06	1975-04-01	Syva Co	Enzyme immunoassays with glucose-6-phosphate dehydrogenase
US4272541A (en)	1978-06-02	1981-06-09	Miles Laboratories, Inc.	7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4464378A (en)	1981-04-28	1984-08-07	University Of Kentucky Research Foundation	Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
CA1188989A (fr)	1981-05-21	1985-06-18	Richard R. Scherschlicht	Nonapeptide pour le traitement des symptomes du sevrage
US4604365A (en)	1981-06-02	1986-08-05	Electro-Nucleonics, Inc.	Immunoprecipitation assay
US4462941A (en)	1982-06-10	1984-07-31	The Regents Of The University Of California	Dynorphin amide analogs
JPS59208119A (ja) *	1983-05-13	1984-11-26	Sankei Giken Kogyo Kk	触媒コンバ−タ
US4499096A (en)	1983-11-18	1985-02-12	Lotsof Howard S	Rapid method for interrupting the narcotic addiction syndrome
US5266574A (en) *	1984-04-09	1993-11-30	Ian S. Zagon	Growth regulation and related applications of opioid antagonists
US4626539A (en)	1984-08-10	1986-12-02	E. I. Dupont De Nemours And Company	Trandermal delivery of opioids
US4573995A (en) *	1984-10-09	1986-03-04	Alza Corporation	Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en)	1984-11-30	1985-01-09	Reckitt & Colmann Prod Ltd	Analgesic compositions
DE3587616D1 (de) *	1984-12-22	1993-11-11	Sanol Arznei Schwarz Gmbh	Wirkstoffpflaster.
US4806341A (en)	1985-02-25	1989-02-21	Rutgers, The State University Of New Jersey	Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4587243A (en)	1985-07-15	1986-05-06	Lotsof Howard S	Rapid method for interrupting the cocaine and amphetamine abuse syndrome
US5316759A (en)	1986-03-17	1994-05-31	Robert J. Schaap	Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8625941D0 (en) *	1986-10-30	1986-12-03	Sandoz Ltd	Substituted alpha-amino acids
US4857523A (en)	1988-07-18	1989-08-15	Nda International, Inc.	Rapid method for attenuating the alcohol dependency syndrome
US5629307A (en)	1989-10-20	1997-05-13	Olney; John W.	Use of ibogaine in reducing excitotoxic brain damage
US5075341A (en)	1989-12-01	1991-12-24	The Mclean Hospital Corporation	Treatment for cocaine abuse
DE4010079A1 (de)	1990-03-29	1991-10-02	Lohmann Therapie Syst Lts	Pharmazeutische formulierung zur behandlung des alkoholismus
US5026697A (en)	1990-05-30	1991-06-25	Nda International, Inc.	Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome
US5152994A (en)	1990-05-31	1992-10-06	Lotsof Howard S	Rapid method for interrupting or attenuating poly-drug dependency syndromes
US5283247A (en)	1991-02-06	1994-02-01	Research Corporation Technologies, Inc.	Anticonvulsant substituted quinazolones
US5149538A (en)	1991-06-14	1992-09-22	Warner-Lambert Company	Misuse-resistive transdermal opioid dosage form
US5290784A (en)	1991-07-18	1994-03-01	Yueqian Qu	Aconitane derivatives used as a medication to treat addiction
DE69320646T2 (de)	1992-04-10	1999-01-14	Merrell Pharmaceuticals Inc., Cincinnati, Ohio	Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
KR950701818A (ko)	1992-06-12	1995-05-17	원본미기재	탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
US5256669A (en) *	1992-08-07	1993-10-26	Aminotek Sciences, Inc.	Methods and compositions for treating acute or chronic pain and drug addiction
WO1994006426A1 (fr)	1992-09-21	1994-03-31	Qin Bo Yi	Procedes d'identification et d'utilisation d'analgesiques opioides de faible dependance ou de non dependance
US5580876A (en)	1992-09-21	1996-12-03	Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
CN1042895C (zh)	1992-09-23	1999-04-14	曲曰谦	治疗吸毒者戒断综合症及脱瘾的药物组合物
AU4066693A (en)	1992-12-23	1994-07-19	Bernhard Hugemann	Compacted drug body for use in the mechanical generation of inhalable active-substance particles
US5865444A (en)	1994-03-21	1999-02-02	Deere & Company	Body leveling suspension including a pivoting arrangement
JP2819236B2 (ja)	1994-05-06	1998-10-30	日東電工株式会社	経皮吸収製剤
US5552406A (en)	1994-06-17	1996-09-03	The Mclean Hospital Corporation	Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
FR2721945B1 (fr)	1994-07-04	1996-10-18	David Fabrice	Accroissement genique, un procede d'amplicication genique isotherme et ses applications
AU4613296A (en)	1994-07-25	1996-04-19	Nda International, Inc.	A method of treating chemical dependency in mammals and a composition therefor
US5591738A (en) *	1994-10-14	1997-01-07	Nda International, Inc.	Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US5760044A (en)	1996-05-16	1998-06-02	Archer; Sydney	Method for treating cocaine and amphetamine dependency
US6451806B2 (en) *	1999-09-29	2002-09-17	Adolor Corporation	Methods and compositions involving opioids and antagonists thereof
US6864271B2 (en)	2002-11-12	2005-03-08	The Foundation For The Lsu Health Sciences Center	Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
AU2004200486B2 (en)	2003-02-12	2007-06-07	Samsung Electronics Co., Ltd.	Complex wireless service apparatus using wired and wireless communication systems and method thereof
US6806291B1 (en) *	2003-10-09	2004-10-19	The Foundation For The Lsu Health Sciences Center	Analgesic compounds, their synthesis and pharmaceutical compositions containing them

1998
- 1998-09-03 ES ES98944698T patent/ES2224430T3/es not_active Expired - Lifetime
- 1998-09-03 EP EP03075683A patent/EP1327447B1/fr not_active Expired - Lifetime
- 1998-09-03 CA CA2302754A patent/CA2302754C/fr not_active Expired - Fee Related
- 1998-09-03 EP EP10180121.5A patent/EP2338494B1/fr not_active Expired - Lifetime
- 1998-09-03 EP EP10170898A patent/EP2246058A1/fr not_active Withdrawn
- 1998-09-03 ES ES10180121T patent/ES2435722T3/es not_active Expired - Lifetime
- 1998-09-03 IL IL13479698A patent/IL134796A0/xx active IP Right Grant
- 1998-09-03 EP EP98944698A patent/EP1009407B1/fr not_active Expired - Lifetime
- 1998-09-03 WO PCT/US1998/018284 patent/WO1999011250A2/fr not_active Ceased
- 1998-09-03 AT AT98944698T patent/ATE265213T1/de active
- 1998-09-03 AU AU92174/98A patent/AU754088B2/en not_active Ceased
- 1998-09-03 ES ES03075683T patent/ES2395268T3/es not_active Expired - Lifetime
- 1998-09-03 DE DE69823520T patent/DE69823520T2/de not_active Expired - Lifetime
- 1998-09-03 AT AT03075683T patent/ATE510542T1/de active
2000
- 2000-02-29 IL IL134796A patent/IL134796A/en not_active IP Right Cessation
2007
- 2007-04-06 US US11/784,343 patent/US7754710B2/en not_active Expired - Fee Related
2010
- 2010-06-08 US US12/796,241 patent/US20100311722A1/en not_active Abandoned
- 2010-06-08 US US12/796,249 patent/US8178524B2/en not_active Expired - Fee Related
- 2010-06-08 US US12/796,247 patent/US20100311723A1/en not_active Abandoned
- 2010-06-15 US US12/815,908 patent/US20100311725A1/en not_active Abandoned
2011
- 2011-12-08 US US13/315,127 patent/US20120083485A1/en not_active Abandoned

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9911250A2 *

Also Published As

Publication number	Publication date
IL134796A (en)	2008-11-26
CA2302754C (fr)	2011-11-08
EP2246058A1 (fr)	2010-11-03
EP1327447B1 (fr)	2011-05-25
DE69823520T2 (de)	2005-05-12
ES2395268T3 (es)	2013-02-11
US20120083485A1 (en)	2012-04-05
AU9217498A (en)	1999-03-22
US8178524B2 (en)	2012-05-15
WO1999011250A3 (fr)	1999-08-05
US20100311723A1 (en)	2010-12-09
ES2224430T3 (es)	2005-03-01
US20070185085A1 (en)	2007-08-09
US20100311722A1 (en)	2010-12-09
US20100311725A1 (en)	2010-12-09
EP2338494B1 (fr)	2013-07-10
EP1009407B1 (fr)	2004-04-28
EP2338494A1 (fr)	2011-06-29
IL134796A0 (en)	2001-04-30
ATE510542T1 (de)	2011-06-15
CA2302754A1 (fr)	1999-03-11
WO1999011250A2 (fr)	1999-03-11
US20100311724A1 (en)	2010-12-09
ES2435722T3 (es)	2013-12-23
US7754710B2 (en)	2010-07-13
ATE265213T1 (de)	2004-05-15
DE69823520D1 (de)	2004-06-03
AU754088B2 (en)	2002-11-07
EP1327447A1 (fr)	2003-07-16

Publication	Publication Date	Title
AU754088B2 (en)	2002-11-07	Noribogaine in the treatment of pain and drug addiction
US7220737B1 (en)	2007-05-22	Noribogaine in the treatment of pain and drug addiction
US3966940A (en)	1976-06-29	Analgetic compositions
US3773955A (en)	1973-11-20	Analgetic compositions
JP2000508341A (ja)	2000-07-04	片頭痛の治療法及び薬効の強化組成物
WO2014143201A1 (fr)	2014-09-18	Procédé pour le traitement avec la noribogaïne de l'addiction de patients sous méthadone
EP1169040A2 (fr)	2002-01-09	Utilisation de flupirtine pour le traitement de la fibromyalgie et d'affections associees a la fibromyalgie
JP2003520234A (ja)	2003-07-02	薬物中毒の治療方法
AU2021409812A2 (en)	2023-08-03	Methods for delay of ejaculation in human males
Levi et al.	2002	A review of chemical agents in the pharmacotherapy of addiction
US20240342156A1 (en)	2024-10-17	Methods for treating pain
KR20220113411A (ko)	2022-08-12	KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
Kutz et al.	2001	Rapid heroin detoxification using a single high dose of buprenorphine
AU2003200404B2 (en)	2006-06-29	Noribogaine in the treatment of pain and drug addiction
MXPA00002211A (en)	2002-02-26	Noribogaine in the treatment of pain and drug addiction
Moore	1984	Clinical pharmacology of opioid analgesics
EP0013110B1 (fr)	1982-09-29	Composition analgésique
JP2005502633A (ja)	2005-01-27	ニコチン依存症に対する薬物療法のための活性物質配合体
Maxwell et al.	1990	Naloxone

Legal Events

Date	Code	Title	Description
2000-05-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-06-21	17P	Request for examination filed	Effective date: 20000323
2000-06-21	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
2001-01-24	17Q	First examination report despatched	Effective date: 20001211
2002-08-28	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 31/55 A, 7A 61P 25/36 B
2002-09-18	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 31/55 A, 7A 61P 25/36 B
2002-09-21	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2002-10-02	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 31/55 A, 7A 61P 25/36 B
2003-04-04	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2004-03-12	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2004-04-28	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
2004-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040428 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040428
2004-04-28	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2004-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2004-05-04	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2004-05-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER & CIE SA
2004-06-02	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2004-06-03	REF	Corresponds to:	Ref document number: 69823520 Country of ref document: DE Date of ref document: 20040603 Kind code of ref document: P
2004-07-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040728 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040728
2004-09-03	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040903 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040903
2004-12-31	ET	Fr: translation filed
2005-03-01	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2224430 Country of ref document: ES Kind code of ref document: T3
2005-03-04	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2005-03-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2005-04-20	26N	No opposition filed	Effective date: 20050131
2005-06-01	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2008-01-02	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040928
2013-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20130911 Year of fee payment: 16 Ref country code: NL Payment date: 20130910 Year of fee payment: 16 Ref country code: ES Payment date: 20130911 Year of fee payment: 16 Ref country code: CH Payment date: 20130912 Year of fee payment: 16 Ref country code: DE Payment date: 20130904 Year of fee payment: 16 Ref country code: AT Payment date: 20130910 Year of fee payment: 16
2013-11-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20130910 Year of fee payment: 16 Ref country code: GB Payment date: 20130904 Year of fee payment: 16
2013-12-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20130909 Year of fee payment: 16
2015-04-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 69823520 Country of ref document: DE
2015-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2015-05-05	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2015-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MM01 Ref document number: 265213 Country of ref document: AT Kind code of ref document: T Effective date: 20140903
2015-05-27	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20140903
2015-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140904
2015-06-26	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20150529
2015-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150401
2015-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140903 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150401 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140930
2015-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140903 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140903 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140930
2015-10-27	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20151027
2016-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140904